ASP ISOTOPES - THE ENDRA PAPER PUTS A PRICE ON HELIUM. THE STOCK ALREADY PAID IT.

Oct 03, 2026

∙ Paid

SEQH CAPITAL RESEARCH - TEAR SHEET
ASP ISOTOPES - THE ENDRA PAPER PUTS A PRICE ON HELIUM. THE STOCK ALREADY PAID IT.

WHAT THIS REPORT ARGUES

The proposed Noble Africa / ENDRA reverse merger gives investors a private-market mark for ASPI’s Renergen interest, but the report argues that the implied valuation only works if Phase 2 helium ultimately contracts at prices materially above the company’s current base assumptions.
The core issue is not whether helium is scarce. It is whether Renergen can convert that scarcity into long-term contracted helium prices high enough to justify a capital-intensive Phase 2 project and the funding dilution required to build it.

The deal mark

Third-party investors are contributing roughly $30 million for about 7 percent of the combined company, implying a post-money Noble Africa value of approximately $400 million to $462 million.
At the central mark, ASPI’s approximately 89 percent interest in Noble Africa is worth about $381 million, or roughly $2.49 per ASPI share.
That is about 147 percent of ASPI’s enterprise value, creating an apparent disconnect between the private placement mark and ASPI’s public-market valuation.
The report’s conclusion is that the structure is efficient as a low-cost route to a Nasdaq listing, but the placement mark should not automatically be treated as a reliable public-market value once Noble Africa begins trading with a limited free float.

Phase 2 is expected to produce roughly 900 Mcf per day of liquid helium and 34,000 GJ per day of hydrocarbons, with management targeting more than $360 million of revenue.
The project is estimated to require approximately $1.15 billion to $1.2 billion of capex, with up to $750 millionof conditional senior debt from the U.S. DFC and Standard Bank.
At management’s reference price of $600/Mcf helium, SEQH estimates a 13.8 percent levered equity IRR, below its assumed 16 percent cost of equity.
The report calculates that Phase 2 requires approximately $759/Mcf helium to meet the 16 percent equity hurdle, while its unlevered economics require closer to $1,084/Mcf to clear the assumed project WACC.

At ASPI’s October 2 closing price of $2.92, the report reverse-solves an implied Phase 2 helium price of about $882/Mcf if FID is certain, or about $959/Mcf using a 55 percent FID probability.
In other words, the stock appears to discount helium economics roughly 47 to 60 percent above the company’s current contracted reference price.
That makes long-term helium contract pricing the most important variable in the entire ASPI / Noble Africa investment case.

Phase 1 is important less for its standalone valuation than for proving that the Virginia Gas Project can operate continuously before lenders commit major capital to Phase 2.
The report highlights a capacity discrepancy: management has referenced both 70 Mcf per day of liquid helium and 250 kg per day, which converts to approximately 52 Mcf per day, about 25 percent lower.
LNG is comparatively well contracted, with roughly 75 percent of Phase 1 volume under take-or-pay agreements, while only around 15 percent of helium volume is contracted despite helium representing roughly half of modeled Phase 2 revenue.
That leaves the helium book as both the biggest upside option and the biggest commercial risk.

ASPI had about $254.9 million of cash and short-term investments at June 30, 2026, but the report estimates Phase 2 needs roughly $350 million to $450 million of equity after debt and placement proceeds.
ASPI is also committing $20 million to the Noble Africa placement and has expanded its term-loan capacity to Renergen from $120 million toward $200 million.
The report argues that every path to funding the Phase 2 equity requirement dilutes someone: NOBA follow-on equity dilutes ASPI’s stake, ASPI intercompany loans consume parent liquidity, and a parent-level raise dilutes ASPI shareholders directly.

The reverse merger creates a visible mark for ASPI’s helium exposure, but the report argues that the public stock is already pricing a substantial improvement in Phase 2 helium economics.
The key question is whether Renergen can secure long-duration take-or-pay helium contracts above roughly $759/Mcf, while keeping Phase 2 capex close to current estimates and proving Phase 1 operational reliability.
The report’s Monte Carlo sum-of-the-parts centers around $2.59 per share, with only about a 22.6 percentprobability of exceeding the $2.92 reference price under its rational-FID framework.

What readers get BELOW in the full PDF
Upgrade to access the complete transaction and helium-economics analysis, including:

The full Noble Africa / ENDRA reverse-merger structure, ownership math, placement valuation, and listing-cost analysis.
Phase 1 operating forensics, including the helium-unit reconciliation, LNG versus helium offtake coverage, and first-shipment milestones.
The complete Phase 2 project model, including capex, debt, IRR, NPV, helium-price, availability, and delay sensitivities.
A detailed review of ASPI’s funding needs, QLE note conversion, term-loan exposure, dilution risk, and NOBA free-float dynamics.
The full 20,000-path Monte Carlo sum-of-the-parts, catalyst calendar, scenario framework, and the exact observations that would prove the helium case right or wrong.